Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Cardioprotection With Dexrazoxane For Doxorubicin-containing Therapy In Advanced Breast Cancer.

S. Swain, F. Whaley, M. Gerber, S. Weisberg, M. York, D. Spicer, S. Jones, S. Wadler, A. Desai, C. Vogel, J. Speyer, A. Mittelman, S. Reddy, K. Pendergrass, E. Vélez-García, M. Ewer, J. Bianchine, R. Gams
Published 1997 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
PURPOSE To determine the cardioprotective effect of dexrazoxane (DZR) used in a doxorubicin-based combination therapy in advanced breast cancer. PATIENTS AND METHODS Between November 1988 and January 1991, 534 patients with advanced breast cancer were randomized to two multicenter, double-blind studies (088001 and 088006). Patients received fluorouracil, doxorubicin, and cyclophosphamide (FAC) with either DZR (DZR-to-doxorubicin ratio, 10:1) or placebo (PLA) every 3 weeks and were monitored with serial multiplegated acquisition (MUGA) scans. RESULTS The hazards ratio (HR) of PLA to DZR for a cardiac event, which was predefined ejection fraction changes or congestive heart failure (CHF), was 2.63 (95% confidence interval [CI], 1.61 to 4.27; P < .001) for 088001 and 2.00 (95% CI, 1.01 to 3.96; P = .038) for 088006. The objective response rates for 088001 were 46.8% for DZR and 60.5% for PLA, a difference of 14% (95% CI, -25% to -2%; P = .019), and for 088006 were 53.7% for DZR and 49.3% for PLA, a difference of 4% (95% CI, -13% to 22%; P = .63). Time to progression and survival were not significantly different between treatment arms in either study. Toxicities on the DZR arms included lower granulocyte and platelet counts at nadir (P = .009 and P = .004, respectively) and more pain on injection (P = .001), with no difference in the rates of fever, infection, or hemorrhage. CONCLUSION DZR had a significant cardioprotective effect as measured by noninvasive testing and clinical CHF. One of the two studies (088001) showed a lower response rate with DZR, but time to progression and survival were not significantly different. DZR is the first agent shown to reduce cardiotoxicity from doxorubicin.
This paper references
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
S. Legha (1982)
ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.
J. Speyer (1992)
Reduction of chronic daunorubicin cardiotoxicity by ICRF-187 in rabbits.
E. Herman (1981)
Antitumour Activity in a Series of bisDiketopiperazines
A. Creighton (1969)
Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.
A. Weiss (1976)
A prospective randomized trial of ICRF-187 for prevention of cumulative doxorubicin-induced cardiac toxicity in women with breast cancer.
J. Speyer (1990)
Prevention of the Cardiotoxic Effects of Adriamycin and Daunomycin in the Isolated Dog Heart 1
E. Herman (1972)
Montreal General Hospital
W. Storrar (1954)
Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.
R. G. Schwartz (1987)
Adriamycin (NSC 123127) cardiomyopathy. An overview with determination of risk factors
R. A. Minow (1975)
Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.
J. Speyer (1988)
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy.
F. Torti (1983)
Reduction in doxorubicin toxicity following liposomal delivery.
R. Sells (1987)
Toxicity and response criteria of the Eastern Cooperative Oncology Group
M. Oken (1982)
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
S. Swain (1997)
Risk factors for doxorubicin-induced congestive heart failure.
D. V. Von Hoff (1979)
Lethal and sublethal effects of the combination of doxorubicin and the bisdioxopiperazine, (+)-1,2,-bis (3-5-dioxopiperazinyl-1-yl) propane (ICRF 187), on murine sarcoma S180 in vitro.
S. Wadler (1987)
Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response.
C. Myers (1977)
Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study.
M. Zalupski (1991)
Use of anionic liposomes for the reduction of chronic doxorubicin-induced cardiotoxicity.
E. Forssen (1981)
Variability in sequential measures of left ventricular performance assessed with radionuclide angiocardiography.
R. Marshall (1978)
Improving the quality of life during chemotherapy for advanced breast cancer. A comparison of intermittent and continuous treatment strategies.
A. Coates (1987)
A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.
K. K. Jain (1985)
Early anthracycline cardiotoxicity.
M. Bristow (1978)
Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation
M. Billingham (1977)
Modification of some of the toxic effects of daunomycin (NSC-82,151) by pretreatment with the antineoplastic agent ICRF 159 (NSC-129,943).
E. Herman (1974)
Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast.
J. Speyer (1985)

This paper is referenced by
26 Drug-Induced Cardiomyopathies
J. Klimas (2012)
Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.
S. Swain (1997)
Editorial: Antidotes and rescue therapies.
R. Y. Wang (2012)
Cardiotoxicity of cytotoxic drugs.
K. Schimmel (2004)
Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
H. Babiker (2018)
Assessment of Tiron as a cardioprotective agent
Oana Chiuzbaian (2019)
Cardiovascular Complications of Cancer Therapeutics
A. Khakoo (2011)
Protection against doxorubicin-induced cardiotoxicity in weanling rats by dexrazoxane
P. Della Torre (1999)
Anthracycline-induced cardiotoxicity in children and young adults.
A. Giantris (1998)
Pharmacologic Prevention of Anthracycline-Induced Cardiomyopathy
Kuldeep Maradia (2009)
The flavonoid quercetin: possible solution for anthracycline-induced cardiotoxicity and multidrug resistance.
J. Czepas (2014)
Cardioprotective Effect of Marine Astaxanthin on Doxorubicin-Induced Cardiotoxicity in Normal Rats
Ali Alqahtani (2019)
In reply [2]
C. Schwartz (2007)
The role of antioxidants in the era of cardio-oncology
Duncan T. Vincent (2013)
Anthracycline versus nonanthracycline adjuvant therapy for early breast cancer
W. Ding (2018)
Angiotensin Converting Enzyme Inhibitors (ACEI) and doxorubicin pharmacokinetics in women receiving adjuvant breast cancer treatment
A. Blaes (2015)
Cardio-Oncology Preventive Care: Racial and Ethnic Disparities
P. Prasad (2020)
A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non‐hematopoietic solid tumors
L. Mascarenhas (2013)
The benefits of antioxidants ascorbate and glutathione to protect healthy cells in the prevention and treatment of oncological diseases
M. S. Alexander (2016)
The Impact of Rosuvastatin and Omeg-3 on the Antitumoral Activity andCardiotoxicity of Doxorubicin Compared to Captopril Effect in Experimentally-Induced Hepatocellular Carcinoma in Mice
I. El-Sayed (2018)
Cardiotoxicity and cardiomyopathy in children and young adult survivors of hematopoietic stem cell transplant
S. Rotz (2017)
DNA Topoisomerase Targeting Drugs
A. Thomas (2017)
Cardiac complications of radiation therapy.
A. Gaya (2005)
La quimioterapia y el corazón
J. Plana (2011)
Improved anti-tumor response rate with decreased cardiotoxicity of non-pegylated liposomal doxorubicin compared with conventional doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin: results of a retrospective analysis
G. Batist (2006)
Liposome‐encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first‐line therapy of metastatic breast carcinoma
L. Harris (2002)
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology.
L. Schuchter (2002)
Therapy Insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy
A. Khakoo (2008)
Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
J. Gligorov (2008)
Pulmonary and Cardiovascular Complications of Cancer Therapy
M. Volm (2001)
Cancer treatment-induced cardiotoxicity: a cardiac stem cell disease?
L. Prezioso (2010)
Cardiotoxicité des traitements anticancéreux dans le contexte du cancer du sein métastasé
Elir Ferrari (2010)
See more
Semantic Scholar Logo Some data provided by SemanticScholar